Bcl6-Targeting PROTAC Compounds for Selective Protein Degradation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Bcl6-related diseases, such as lymphomas, lack effective compounds that can inhibit and degrade Bcl6 protein safely and with high efficacy.
Innovation Solution
Development of novel compounds represented by general formula (I) or its stereoisomers, deuterated forms, solvates, prodrugs, or pharmaceutically acceptable salts, which target Bcl6 protein and E3 ubiquitin ligases for degradation using PROTAC technology.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for Bcl6-related diseases, then treatment is provided, but efficacy is insufficient and safety is compromised
Solution Approach 1:
The patent introduces PROTAC molecules as intermediary compounds that mediate between the Bcl6 target protein and the cellular degradation machinery (proteasome). These bifunctional molecules contain a Bcl6-binding ligand and an E3 ubiquitin ligase ligand, acting as a bridge to achieve selective Bcl6 degradation without directly inhibiting the protein's function, thereby improving both efficacy and safety
Solution Approach 2:
The patent employs deuterated forms of the compound where hydrogen atoms are replaced with deuterium atoms. This isotopic substitution changes the physical and chemical parameters of the molecule, potentially improving metabolic stability, reducing clearance rates, and enhancing overall drug performance while maintaining the desired Bcl6-targeting activity
2Reliability
If PROTAC technology is applied to target Bcl6, then Bcl6 degradation is achieved, but compound complexity increases
Solution Approach 1:
The PROTAC molecule is segmented into distinct functional modules: a Bcl6-binding ligand portion, a linker region (which may include deuterated segments), and an E3 ubiquitin ligase-binding portion. This segmentation allows each component to perform its specific function independently while being part of an integrated system, facilitating rational design and optimization
Solution Approach 2:
The patent utilizes universal building blocks in the PROTAC design, such as common E3 ligase ligands (e.g., VHL, CRBN binders) and standardized linker architectures. These universal components can be combined with different Bcl6 ligands to create multiple PROTAC variants, reducing the need to de novo design each entire molecule and simplifying the overall development process
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds effectively inhibit and degrade Bcl6, offering improved safety and bioavailability for treating Bcl6-related diseases like cancer.
Implementation Method 1
PROTAC (proteolysis targeting chimera) molecules are a class of bifunctional compounds that can simultaneously bind targeting proteins and E3 ubiquitin ligases
Implementation Method 2
Such compounds can be recognized by proteasomes of cells, causing the degradation of targeting proteins
Data Source
AI summary
The present invention relates to a compound represented by general formula (I) or a stereoisomer, a deuterated form, a solvate, a prodrug, a metabolite, a pharmaceutically acceptable salt or a eutectic thereof, and an intermediate and a pharmaceutical composition thereof, and use thereof in Bcl6-related diseases such as cancer. B-L-K (I).